About VBI Vaccines, Inc. -
VBI Vaccines Inc., formerly SciVac Therapeutics Inc., is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens. It is engaged in developing an experimental CMV vaccine using its eVLP vaccine platform. The vaccine is based on the CMV glycoprotein B antigen and is adjuvanted with aluminum phosphate. The eVLP vaccine technology allows for the expression of envelope glyco-proteins within a lipid-bilayer membrane of a VLP. It is developing a therapeutic vaccine candidate for glioblastoma multiforme (GBM). It is developing a vaccine to prevent respiratory syncytial virus (RSV) infection. It also offers Sci-B-Vac, which is a third-generation hepatitis B vaccine.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: VBIV
Companies Related to VBI Vaccines, Inc. -:
- Previous Close: $4.78
- 50 Day Moving Average: $3.87
- 200 Day Moving Average: $3.50
- 52-Week Range: $2.75 - $5.23
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.29
- P/E Growth: 0.00
- Market Cap: $173.90M
- Outstanding Shares: 36,380,000
Earnings History for VBI Vaccines, Inc. - (NASDAQ:VBIV)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for VBI Vaccines, Inc. - (NASDAQ:VBIV)
Current Year EPS Consensus Estimate: $-0.67 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS
Dividend History for VBI Vaccines, Inc. - (NASDAQ:VBIV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for VBI Vaccines, Inc. - (NASDAQ:VBIV)
Insider Ownership Percentage: 54.50%
Institutional Ownership Percentage: 22.11%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|12/6/2016||Perceptive Advisors Llc||Major Shareholder||Buy||3,383,955||$3.05||$10,321,062.75|| |
|8/14/2015||Perceptive Advisors Llc||Major Shareholder||Buy||650,000||$2.08||$1,352,000.00|| |
|9/30/2013||Murray George Smith||CFO||Buy||3,027||$1.13||$3,420.51|| |
|8/21/2013||Murray George Smith||CFO||Buy||8,973||$1.17||$10,498.41|| |
Latest Headlines for VBI Vaccines, Inc. - (NASDAQ:VBIV)
What is VBI Vaccines, Inc. -'s stock symbol?
VBI Vaccines, Inc. - trades on the NASDAQ under the ticker symbol "VBIV."
Where is VBI Vaccines, Inc. -'s stock going? Where will VBI Vaccines, Inc. -'s stock price be in 2017?
2 equities research analysts have issued 12-month price targets for VBI Vaccines, Inc. -'s shares. Their predictions range from $6.00 to $6.00. On average, they anticipate VBI Vaccines, Inc. -'s stock price to reach $6.00 in the next year.
Who owns VBI Vaccines, Inc. - stock?
VBI Vaccines, Inc. -'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (17.96%).
Who bought VBI Vaccines, Inc. - stock? Who is buying VBI Vaccines, Inc. - stock?
VBI Vaccines, Inc. -'s stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC.
How do I buy VBI Vaccines, Inc. - stock?
Shares of VBI Vaccines, Inc. - can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of VBI Vaccines, Inc. - stock cost?
One share of VBI Vaccines, Inc. - stock can currently be purchased for approximately $4.78.
VBI Vaccines, Inc. - (NASDAQ:VBIV) Chart for Monday, February, 27, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart